EuBiologics Co., Ltd. (206650.KQ)
KRW 12130.0
(-3.58%)
KRW 12130.0
(-3.58%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 24.95 Billion KRW | -3.96% |
| 2022 | 25.99 Billion KRW | 20.97% |
| 2021 | 21.48 Billion KRW | 77.77% |
| 2020 | 12.08 Billion KRW | 35.16% |
| 2019 | 8.94 Billion KRW | 43.62% |
| 2018 | 6.22 Billion KRW | 48.49% |
| 2017 | 4.19 Billion KRW | 63.66% |
| 2016 | 2.56 Billion KRW | 8.34% |
| 2015 | 2.36 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 5.14 Billion KRW | 29.41% |
| 2024 Q2 | 5.62 Billion KRW | 12.18% |
| 2023 Q3 | 6.61 Billion KRW | 0.87% |
| 2023 Q2 | 6.56 Billion KRW | -14.24% |
| 2023 FY | 24.95 Billion KRW | -3.96% |
| 2023 Q1 | 7.65 Billion KRW | -6.79% |
| 2023 Q4 | 3.97 Billion KRW | -39.88% |
| 2022 Q1 | 4.33 Billion KRW | -31.7% |
| 2022 FY | 25.99 Billion KRW | 20.97% |
| 2022 Q3 | 6.49 Billion KRW | -6.6% |
| 2022 Q2 | 6.95 Billion KRW | 60.45% |
| 2022 Q4 | 8.2 Billion KRW | 26.38% |
| 2021 Q3 | 4.37 Billion KRW | -20.93% |
| 2021 Q1 | 5.23 Billion KRW | 0.0% |
| 2021 FY | 21.48 Billion KRW | 77.77% |
| 2021 Q2 | 5.53 Billion KRW | 5.75% |
| 2021 Q4 | 6.34 Billion KRW | 45.03% |
| 2020 FY | 12.08 Billion KRW | 35.16% |
| 2019 FY | 8.94 Billion KRW | 43.62% |
| 2018 FY | 6.22 Billion KRW | 48.49% |
| 2017 FY | 4.19 Billion KRW | 63.66% |
| 2016 FY | 2.56 Billion KRW | 8.34% |
| 2015 FY | 2.36 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 102.52 Billion KRW | 75.655% |
| CMG Pharmaceutical Co., Ltd. | 37.86 Billion KRW | 34.084% |
| Celltrion Pharm, Inc. | 80.93 Billion KRW | 69.161% |
| Huons Global Co., Ltd. | 294.87 Billion KRW | 91.536% |
| DongKook Pharmaceutical Co., Ltd. | 338.16 Billion KRW | 92.619% |
| Enzychem Lifesciences Corporation | 18.7 Billion KRW | -33.445% |
| Humedix Co., Ltd. | 33.04 Billion KRW | 24.463% |
| Boditech Med Inc. | 47.05 Billion KRW | 46.952% |
| FutureChem Co.,Ltd | 9.16 Billion KRW | -172.306% |
| Huons Co., Ltd. | 226.14 Billion KRW | 88.963% |
| BNC Korea Co., Ltd. | 25.19 Billion KRW | 0.948% |
| AptaBio Therapeutics Inc. | 16.45 Billion KRW | -51.714% |